Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone

BACKGROUND: Myostatin antagonists are being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the potential to combine the hypertrophy of myostatin antagonism with the anti-inflammatory and anti-fibrotic eff...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Skelet Muscle
Hoofdauteurs: Iskenderian, Andrea, Liu, Nan, Deng, Qingwei, Huang, Yan, Shen, Chuan, Palmieri, Kathleen, Crooker, Robert, Lundberg, Dianna, Kastrapeli, Niksa, Pescatore, Brian, Romashko, Alla, Dumas, John, Comeau, Robert, Norton, Angela, Pan, Jing, Rong, Haojing, Derakhchan, Katayoun, Ehmann, David E.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2018
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6204036/
https://ncbi.nlm.nih.gov/pubmed/30368252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13395-018-0180-z
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items